Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With Lenvatinib in Renal Cell Carcinoma
NCT07909265Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in renal cell carcinoma (RCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate. Started Apr 2025; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07909265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909265.